Why the study?
Does intermittent transdermal nitroglycerin therapy or increased sublingual nitroglycerin dose prevent cross-tolerance to sublingual nitroglycerin in patients with coronary artery disease?
Population
48 patients with coronary artery disease undergoing diagnostic cardiac catheterization
Comparison
Sublingual nitroglycerin administered to… vs Patients receiving 1 tablet of sublingual…
Design
Cohort
Follow-up
Acute (during cardiac catheterization)
Authors
Loading...
May support intermittent dosing to lessen cross-tolerance; hypothesis-generating and requires randomized confirmation in CAD.
Does intermittent transdermal nitroglycerin therapy or increased sublingual nitroglycerin dose prevent cross-tolerance to sublingual nitroglycerin in patients with coronary artery disease?
Intermittent transdermal nitroglycerin therapy or an increased dose of sublingual nitroglycerin can overcome cross-tolerance in patients with coronary artery disease.
Naito et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: